Pfizer (NYSE: PFE - option chain) shares are rising today after the company gave an update on mid-stage studies of its experimental rheumatoid arthritis drug. A Phase Two study shows PFE's oral JAK-3 inhibitor "demonstrates statistically significant response for patients with rheumatoid arthritis." PFE is currently enrolling patients for a phase 3 study of the treatment. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on PFE.PFE opened this morning at $14.09. So far today the stock has hit a low of $14.05 and a high of $14.65. As of 11:45, PFE is trading at $14.60 up 55 cents (3.9%). The chart for PFE looks neutral and S&P gives PFE a neutral 3 STARS (out of 5) hold ranking.
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
